The HRT Myth That’s Still Hurting Women

Setting the Record Straight on Hormone Therapy

In the summer of 2002, a headline changed the course of women’s health for a generation.

The Women’s Health Initiative — a large, federally funded study — announced that it was stopping one of its arms early. The news: hormone therapy increased the risk of breast cancer, heart disease, stroke, and blood clots. The message that spread, rapidly and loudly, was simple: hormone therapy is dangerous. Women should stop taking it. Providers should stop prescribing it.

And they did. In enormous numbers. Within two years, hormone therapy prescriptions had dropped by more than half. Women who had been managing their symptoms effectively stopped their medication, often abruptly, out of fear. Providers who had been prescribing thoughtfully became reluctant to do so at all. An entire generation of women entered menopause without access to a treatment that, for many of them, would have been both safe and beneficial.

That headline was not wrong, exactly. But it was profoundly incomplete. And the gap between what the study actually showed and what was communicated to the public — and to the medical community — has been quietly harming women ever since.

Twenty years of undertreated menopause. Twenty years of women suffering through symptoms they didn’t have to. Twenty years of increased bone loss, cardiovascular risk, and diminished quality of life — at least in part because of a misread study and a medical culture that overcorrected. That is worth being angry about. And it is worth setting the record straight.

What the WHI Study Actually Found

The Women’s Health Initiative was a genuinely important study — one of the largest randomized controlled trials of hormone therapy ever conducted. But understanding what it found requires understanding who it studied and how.

The population

The average age of participants in the WHI was 63. Most women in the study were more than ten years past menopause. This is a critically important detail, because we now understand — through subsequent research — that the timing of hormone therapy relative to menopause has a profound effect on its risk-benefit profile. Studying women who were a decade or more post-menopause and applying those findings to women in early menopause is a significant methodological problem.

The hormones used

The study used oral conjugated equine estrogen (derived from horse urine) and a synthetic progestin called medroxyprogesterone acetate (MPA). These are specific formulations with specific properties. The results of this study cannot be straightforwardly applied to transdermal estrogen (patches, gels, sprays), to bioidentical progesterone, or to the many other formulations that exist. The WHI studied particular hormones. It did not study hormone therapy as a category.

The actual risk numbers

Even within the study population, the absolute risk increases were small. The relative risk increase for breast cancer, for example, was approximately 26% — which sounds alarming until you understand what that means in absolute terms. In the WHI, this translated to roughly 8 additional cases of breast cancer per 10,000 women per year. For context, that is a smaller increase in absolute risk than drinking a glass of wine per day, being sedentary, or being obese — none of which generate the same level of medical alarm.

The cardiovascular findings were similarly nuanced. Women who started hormone therapy closer to menopause — even within the WHI data — showed different, more favorable patterns than those who started later. This age-related difference was present in the data. It was not prominently featured in the headlines.

The risk numbers that frightened a generation of women and providers were real — but they were absolute risks in a specific population using specific hormones. Applying them universally was always a scientific error. We are still living with the consequences of that error.

What the Science Has Shown Since

In the two decades since the WHI, the evidence on hormone therapy has become substantially more nuanced — and substantially more favorable for many women, particularly those who initiate treatment early.

The timing hypothesis

One of the most significant developments in menopause science since 2002 is the establishment of what researchers call the “timing hypothesis” or the “window of opportunity.” Multiple lines of evidence now suggest that hormone therapy initiated within ten years of the last menstrual period, or before age 60, has a meaningfully different — and more favorable — risk-benefit profile than therapy initiated later.

For cardiovascular health in particular, early initiation of hormone therapy appears to be protective. The same estrogen that posed cardiovascular risk in older, longer post-menopausal women in the WHI may reduce cardiovascular risk when given to younger women closer to menopause. This is not a minor distinction. It is one of the most clinically important findings in menopause medicine in the past two decades.

Transdermal estrogen and blood clot risk

The WHI used oral estrogen. Oral estrogen is processed through the liver during its first pass through the body, which affects clotting factors and increases blood clot risk. Transdermal estrogen — delivered through the skin via patch, gel, or spray — bypasses this first-pass liver metabolism. Multiple studies have found that transdermal estrogen does not carry the same elevated blood clot risk as oral estrogen. This is a clinically significant difference that should inform how hormone therapy is prescribed and discussed.

Bioidentical progesterone vs. synthetic progestins

The WHI used medroxyprogesterone acetate, a synthetic progestin. Subsequent research, including the large French E3N cohort study, has found that micronized bioidentical progesterone — a molecule identical to the progesterone produced by the human body — has a more favorable safety profile, including potentially lower breast cancer risk compared to synthetic progestins. The type of progestogen used in hormone therapy matters, and the conversation has moved well beyond the single formulation studied in the WHI.

Breast cancer risk in context

The breast cancer question remains the one that generates the most fear, and it deserves a careful, honest answer.

For women who use combined estrogen-progestogen therapy, there is a small increased risk of breast cancer associated with longer-term use. This risk appears to be lower with bioidentical progesterone than with synthetic progestins. For women who have had a hysterectomy and use estrogen alone, some studies have actually found a reduced risk of breast cancer.

Crucially, the absolute risk increase remains small for most women — and must be weighed against the known risks of untreated menopause, including cardiovascular disease, osteoporosis, and significantly reduced quality of life. This is a risk-benefit conversation, not a risk-only conversation. And it is a conversation that should be tailored to each individual woman based on her personal and family history.

The Myths Worth Naming Directly

Myth: “HRT causes breast cancer.”

Reality: For some formulations, in some women, with prolonged use, there is a small increased relative risk. For other formulations — particularly estrogen alone and estrogen with bioidentical progesterone — the risk picture is different. The absolute risk increase for most women is small and must be weighed against the benefits and against the risks of no treatment. This is not a yes or no answer.

Myth: “HRT is only for hot flashes.”

Reality: Hormone therapy has FDA-approved indications for vasomotor symptoms (hot flashes and night sweats), genitourinary symptoms, and the prevention of osteoporosis. Beyond these indications, research is actively exploring its role in cardiovascular health, cognitive protection, and mood stabilization. It is a systemic treatment for a systemic transition — not a single-symptom solution.

Myth: “You should only take HRT for the shortest time possible.”

Reality: The “shortest time, lowest dose” guidance emerged directly from the WHI era and was always more cautious than the evidence strictly required. Current guidance from major menopause societies supports individualized duration decisions based on ongoing risk-benefit assessment. For some women, longer-term use is appropriate and supported. There is no universal time limit that applies to every woman.

Myth: “If your symptoms aren’t severe, you don’t need HRT.”

Reality: Symptom severity is one factor in the decision — but it is not the only one. The long-term health consequences of estrogen loss — bone loss, cardiovascular risk, genitourinary changes, cognitive effects — occur regardless of whether a woman’s hot flashes are severe. A woman with mild symptoms may still have compelling reasons to consider hormone therapy based on her risk profile for these longer-term outcomes.

Myth: “All hormone therapy is the same.”

Reality: The type of estrogen, the route of delivery, the type of progestogen, the dose, and the timing of initiation all affect the risk-benefit profile in meaningful ways. A woman on transdermal estradiol with micronized progesterone initiated at age 50 is in a fundamentally different clinical situation than a woman on oral conjugated equine estrogen with synthetic progestin initiated at age 63. Treating these as equivalent is a clinical error.

What the Major Medical Societies Now Say

It is worth noting that the leading professional organizations in menopause medicine have substantially updated their positions since 2002. The Menopause Society (formerly the North American Menopause Society), the British Menopause Society, and the International Menopause Society have all published position statements affirming that:

• For healthy women under 60 or within ten years of menopause, the benefits of hormone therapy generally outweigh the risks for the treatment of vasomotor symptoms and prevention of bone loss.

• The risks of hormone therapy have been overstated and the benefits understated in public discourse.

• Individualized decision-making based on a woman’s personal history, risk factors, and preferences should guide treatment decisions.

• Fear of hormone therapy based on the original WHI reporting is not warranted for most women who are appropriate candidates.

These are not fringe positions. They represent the current consensus of the medical organizations specifically dedicated to menopause care. The science has moved. The clinical guidance has moved. The fear, unfortunately, has been slower to follow.

This Is About More Than Hormone Therapy

We want to close this series — and this post — with something broader than a discussion of any single treatment.

The story of the WHI and its aftermath is a story about what happens when women’s health is not prioritized, when research findings are communicated carelessly, when the medical system overcorrects out of caution without fully accounting for the costs of undertreating. Those costs were borne entirely by women. In bone density. In cardiovascular events. In years of disrupted sleep, unaddressed anxiety, painful intimacy, and diminished quality of life.

The women who went through menopause in the decade after 2002 deserved better. The women going through it now deserve better. And better starts with accurate information, honest conversations, and providers who are working from current evidence rather than twenty-year-old headlines.

You are entitled to the current science. You are entitled to a provider who has engaged with it. You are entitled to a conversation that treats you as an intelligent adult capable of weighing your own risks and making your own decisions. That is not too much to ask. It is the minimum.

Where to Go From Here

If you have read through this series — all six posts — you now have more information about perimenopause, menopause, and hormone therapy than most women ever receive from the healthcare system. That knowledge belongs to you. Use it.

• Talk to your provider. Bring your questions. Use the language from Post 4. Push back if you need to.

• Seek out providers with specific menopause expertise if your current provider is not engaging with the current evidence.

• Understand that your symptoms are real, your risks are real, and your options are real — and that none of them should be minimized.

• Share this series with women in your life who are navigating this transition. The more women who have access to this information, the better.

At Seagrass Integrated Mental Health, this is the kind of care we believe in: whole-person, evidence-based, and deeply respectful of the women who walk through our door. If you are ready to have the conversation that no one has had with you yet, we are ready to have it.

About This Series

This is the final post in our six-part Women’s Health Series on perimenopause and menopause. If you’ve joined us mid-series, the full series is available on our blog:

• Post 1: It’s Not Just You — What Your Body Is Actually Going Through in Perimenopause

• Post 2: Estrogen Is Everywhere — Why Hormones Matter Far Beyond Fertility

• Post 3: The Silent Risks After Menopause — Heart Disease, Bone Loss, and What No One Told You

• Post 4: How to Talk to Your Provider About Hormone Therapy — and Why You Should

• Post 5: Your Anxiety Isn’t “Just Stress” — The Hormonal Truth Behind Mood Changes in Perimenopause

• Post 6: The HRT Myth That’s Still Hurting Women — Setting the Record Straight

You’ve Done the Reading. Now Let’s Have the Conversation.

If this series has raised questions, clarified concerns, or given you language for a conversation you’ve been trying to have — we’d love to be part of what comes next. Schedule an appointment with our team at Seagrass Integrated Mental Health. We’re here for the whole picture.

This post is for educational purposes and does not constitute medical advice. The information presented reflects current evidence and the positions of major menopause medical societies as of the time of writing. Individual risk-benefit decisions regarding hormone therapy should always be made in consultation with a qualified healthcare provider based on your personal health history, risk factors, and preferences. The science in this area continues to evolve.